Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs Viatris Inc — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $10.27 (market cap $3.97B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 5× Direxion Daily TSLA Bull 2X Shares's market cap, and Viatris Inc pays a 2.75% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily TSLA Bull 2X Shares for 15 Days and Viatris Inc for 57 Days on average.
| TSLL | VTRS | |
|---|---|---|
Market Cap | $3.97B | $20.03B |
Volume | 38,458,237 | 14,109,977 |
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $18.27 |
52-Week Low | $6.74 | $9.74 |
Typical Hold Time | 15 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.15, down 1.55% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights its sensitivity to Tesla's performance, with a rally noted ahead of the Cybercab event. The ETF's structure amplifies daily returns, making it highly volatile and dependent on Tesla's stock movements.
The outlook for TSLL is tied directly to Tesla's stock volatility and news flow. Investment opportunities exist for traders seeking leveraged exposure to Tesla's upside, but risks include significant volatility decay and the potential for amplified losses. Investors should be cautious of the ETF's daily reset mechanism, which can lead to underperformance over time compared to holding Tesla stock directly.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
